Presenters: Ankit Agrawal, Senior Director, Commercial Strategy, Curia Anish Parikh, Vice President, Drug Product Sales & Marketing, Curia Listen in as our experts discuss: The shortage of sterile manufacturing capacity within CDMOs given the Covid-19 pandemic The push to keep manufacturing within US borders The immense coordination to work with our clients to find a vaccine for Covid-19 The shortage of supplies (components, gowning, etc.)View resource
More from Curia
While large molecules continue to advance in drug development pipelines, small molecule Active Pharmaceutical Ingredients (APIs) still retain their historical dominance among new drug applications (NDAs). However, the last few years have seen the lin...